Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-7213aca022d38d404e1e1e0d23413856"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-7213aca022d38d404e1e1e0d23413856"/>
<resource>
<Composition>
<id value="composition-en-7213aca022d38d404e1e1e0d23413856"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-7213aca022d38d404e1e1e0d23413856"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-7213aca022d38d404e1e1e0d23413856</b></p><a name="composition-en-7213aca022d38d404e1e1e0d23413856"> </a><a name="hccomposition-en-7213aca022d38d404e1e1e0d23413856"> </a><a name="composition-en-7213aca022d38d404e1e1e0d23413856-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1537/005</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - nexpovio</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1537/005"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp7213aca022d38d404e1e1e0d23413856"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - nexpovio"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What NEXPOVIO is and what it is used for</li><li>What you need to know before you take NEXPOVIO</li><li>How to take NEXPOVIO</li><li>Possible side effects</li><li>How to store NEXPOVIO</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What nexpovio is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What nexpovio is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>NEXPOVIO contains the active substance selinexor. Selinexor is a cancer medicine known as an XPO1 inhibitor. It blocks the action of a substance called XPO1 that transports proteins from the cell nucleus into the cell cytoplasm. Some cell proteins must be in the nucleus in order to function properly.</p><p>By blocking XPO1 function, selinexor prevents the exit of certain proteins out of the nucleus, and interfering with the continued growth of cancer cells, and leading to the death of cancer cells.</p><p>What NEXPOVIO is used for</p><p>NEXPOVIO is used to treat adult patients with multiple myeloma that has come back after treatment. NEXPOVIO is used</p><ul><li>together with two other medicines called bortezomib and dexamethasone in people who had at least one other prior treatment. OR</li><li>together with dexamethasone in patients who have received at least four previous types of myeloma treatment and whose disease cannot be controlled with prior medicines used to treat multiple myeloma.</li></ul><p>Multiple myeloma is a cancer which affects a type of blood cell called the plasma cell. A plasma cell normally produces proteins to fight infections. People with multiple myeloma have cancerous plasma cells, also called myeloma cells, which can damage bones and kidneys and increase the risk of infection. Treatment with NEXPOVIO kills myeloma cells and reduces symptoms of the disease.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take nexpovio"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take nexpovio"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take NEXPOVIO If you are allergic to selinexor or any of the other ingredients of this medicine (listed in section 6).</p><p>Warnings and precautions Talk to your doctor or pharmacist before taking NEXPOVIO and during treatment if you:</p><ul><li>have or have had bleeding problems.</li><li>have had a recent infection or get an infection.</li><li>have nausea, vomiting or diarrhoea.</li><li>lose your appetite or lose weight.</li><li>have confusion and dizziness.</li><li>have a decrease in your blood sodium levels (hyponatraemia). have a new or worsening cataract. Your doctor will examine you and you will be monitored closely during treatment. Before starting NEXPOVIO and during treatment, you will have blood tests to check that you have enough blood cells.</li></ul><p>Children and adolescents NEXPOVIO should not be given to children and adolescents under 18 years.</p><p>Other medicines and NEXPOVIO Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Pregnancy A pregnancy test is recommended before NEXPOVIO treatment for women able to have children. Do not use NEXPOVIO during pregnancy as it can harm the unborn child. Women who become pregnant while taking NEXPOVIO must immediately stop treatment and inform the doctor.</p><p>Breast-feeding Do not breast-feed during treatment with NEXPOVIO or 1 week after the last dose, as it is unknown whether selinexor or its metabolites are excreted in human milk and cause harm to the breast-fed children.</p><p>Fertility NEXPOVIO may impair fertility in females and males.</p><p>Contraception Women who can become pregnant must use effective contraception during treatment and for at least 1 week after the last dose.</p><p>Men are recommended to use effective contraceptive measures or avoid sexual intercourse with women able to have children during treatment and for at least 1 week after the last dose.</p><p>Driving and using machines NEXPOVIO can cause fatigue, confusion and dizziness. Do not drive or use machines if you get such a reaction while being treated with this medicine.</p><p>NEXPOVIO contains sodium This medicine contains less than 1 mmol sodium (23 mg) per 20 mg tablet, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take nexpovio"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take nexpovio"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is:</p><ul><li>when used together with bortezomib and dexamethasone: 100 mg (5 tablets) once daily, on day 1 of each week, or as directed by your doctor.</li><li>when used with dexamethasone: 80 mg (4 tablets) once daily, on days 1 and 3 of each week, or as directed by your doctor.</li></ul><p>Your doctor may alter your dose if side effects occur. It is important to take this medicine exactly as your doctor has told you to avoid dosing errors.</p><p>Method of use Swallow NEXPOVIO tablets whole with a glassful of water, either with food or between meals. Do not chew, crush, divide or break the tablets in order to prevent risk of skin irritation from the active substance.</p><p>Duration of use Your doctor will let you know the duration of treatment based on how you are responding to treatment and side effects.</p><p>If you take more NEXPOVIO than you should Call your doctor or go to the nearest hospital emergency room right away. Take your box of NEXPOVIO tablets with you.</p><p>If you forget to take NEXPOVIO Do not take a double dose to make up for a forgotten dose. Also, do not take an extra dose if you vomit after taking NEXPOVIO. Take your next dose when scheduled.</p><p>If you stop taking NEXPOVIO Do not stop taking or change your dose of NEXPOVIO without your doctor s approval. However, if you become pregnant while taking NEXPOVIO, you must immediately stop treatment and inform your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor or nurse immediately if you notice any of the following side effects.</p><p>NEXPOVIO may cause the following serious side effects:</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>reduced number of blood platelets Your doctor will carry out blood tests before you start taking NEXPOVIO, and as needed during and after treatment. These tests will be more frequent during the first two months of treatment to monitor your blood platelet counts. Your doctor may stop treatment or adjust the dose based on your platelet counts. Tell your doctor immediately if you have signs of reduced number of blood platelets such as:</li></ul><ul><li><p>easy or excessive bruising</p></li><li><p>skin changes that appear as a rash of pinpoint-sized reddish-purple spots</p></li><li><p>prolonged bleeding from cuts</p></li><li><p>bleeding from your gums or nose</p></li><li><p>blood in your urine or stools</p></li></ul><ul><li>reduced number of red and white blood cells, including neutrophils and lymphocytes. Your doctor will carry out blood tests to monitor your red and white blood cell counts before you start taking NEXPOVIO and as needed during and after treatment. These tests will be more frequent during the first two months of treatment. Your doctor may stop treatment or adjust the dose based on your blood cell counts or may treat you with other medicines to increase cell counts. Tell your doctor immediately if you have signs of reduced neutrophils such as a fever.</li><li>fatigue Inform your doctor if you experience new or worsening fatigue. Your doctor may adjust the dose in case of persistent or worsening fatigue.</li><li>nausea, vomiting, diarrhoea Inform your doctor immediately if you develop nausea, vomiting or diarrhoea. Your doctor may adjust the dose or stop treatment based on the severity of your symptoms. In addition, your doctor may prescribe you medicines to take before or during NEXPOVIO treatment to prevent and treat nausea and/or vomiting and/or diarrhoea.</li><li>decreased appetite and/or weight Your doctor will weigh you before you start taking NEXPOVIO and as needed during and after treatment. This will be more frequent during the first two months of treatment. Tell your doctor if you lose your appetite and if you lose weight. Your doctor may adjust the dose in case of reduced appetite and weight and/or prescribe medicines to increase your appetite. Maintain adequate fluid and caloric intake throughout your treatment.</li><li>reduced sodium level Your doctor will carry out blood tests to check your sodium level before you start taking NEXPOVIO, and as necessary during and after treatment. These tests will be more frequent during the first two months of treatment. Your doctor may adjust the dose and/or prescribe salt tablets or fluids based on your sodium level.</li><li>confusional state and dizziness Inform your doctor if you experience confusion. Avoid situations where dizziness or confusional state may be a problem and do not take other medications that may cause dizziness or confusional state without talking to your doctor. Do not drive or operate machines if you experience any confusion or dizziness until it resolves. Your doctor may adjust the dose to reduce these symptoms.</li><li>cataract Inform your doctor if you experience symptoms of cataract such as double vision, sensitivity to light or glare. If you notice changes with your vision, your doctor may request an eye examination by an eye specialist (an ophthalmologist) and you may need eye surgery to remove the cataract and restore your vision.</li></ul><p>Tell your doctor or nurse immediately if you notice any of the other following side effects as listed below.</p><p>Other possible side effects are:</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li><p>Pneumonia</p></li><li><p>Upper respiratory tract infection</p></li><li><p>Bronchitis</p></li><li><p>Viral infection of the nose and throat (Nasopharyngitis)</p></li><li><p>Damage to nerves in the hands and feet that can cause tingling and numbness (peripheral neuropathy)</p></li><li><p>Bleeding from nose</p></li><li><p>Headache</p></li><li><p>Dehydration</p></li><li><p>Increased blood sugar level</p></li><li><p>Decreased potassium level</p></li><li><p>Loss of sleep (insomnia)</p></li><li><p>Impaired sense of taste</p></li><li><p>Blurred vision</p></li><li><p>Shortness of breath</p></li><li><p>Cough</p></li><li><p>Abdominal pain</p></li><li><p>Constipation</p></li><li><p>Loss of energy</p></li><li><p>Fever</p></li></ul><p>Common (may affect more than 1 in 100 people)</p><ul><li>Bacterial infection in the blood</li><li>The body normally releases chemicals into the blood stream to fight an infection, when the body s response to these chemicals is out of balance, triggering changes that can damage multiple organ systems (sepsis)</li><li>Reduced number of neutrophils with fever</li><li>Decreased phosphate level</li><li>Increase potassium level</li><li>Decreased calcium level</li><li>Decreased magnesium level</li><li>Mental confusion (hallucination)</li><li>Increased amylase and lipase level</li><li>Increased uric acid level</li><li>Confusing thinking (delirium)</li><li>Fainting (syncope)</li><li>Increase in heart rate (tachycardia)</li><li>Low vision</li><li>Loss of taste</li><li>Taste disorder</li><li>Balance disorder</li><li>Cognitive disorder</li><li>Disturbance in attention</li><li>Memory impairment</li><li>Low blood pressure (hypotension)</li><li>Spinning sensation (vertigo)</li><li>Indigestion, dry mouth, abdominal discomfort</li><li>Flatulence or bloating</li><li>Skin itchiness</li><li>Muscle spasm</li><li>Kidney problems</li><li>General physical health deterioration, gait disturbance, malaise, chills</li><li>Increased levels of liver enzymes (alanine aminotransferase, aspartate amino transferase, and alkaline phosphatase)</li><li>Fall</li><li>Memory impairment, including amnesia</li><li>Increase in muscle enzyme called creatine</li><li>Loss of hair</li><li>Night sweats including excessive sweating</li><li>Lower respiratory tract infection</li><li>Bruise</li></ul><p>Uncommon (may affect up to 1 in 100 people):</p><ul><li>rapid break down of tumour cells that could be potentially life-threatening and cause the symptoms as muscle cramping, muscle weakness, confusion, visual loss or disturbances and shortness of breath (tumour lysis syndrome)</li><li>inflammation of brain that could cause confusion, headache, seizures (encephalopathy)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store nexpovio"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store nexpovio"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister pack, the inner carton, and the outer carton after EXP: The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not use this medicine if you notice any damage or signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What NEXPOVIO contains</p><ul><li>The active substance is selinexor. Each film-coated tablet contains 20 mg selinexor.</li><li>The other ingredients are microcrystalline cellulose, croscarmellose sodium, povidone K30, sodium lauryl sulphate, colloidal silicon dioxide, magnesium stearate. For the tablet coating the ingredients are talc, poly(vinyl alcohol) partially hydrolysed, glyceryl monostearate, polysorbate 80, titanium dioxide, macrogol, indigo carmine aluminium lake and brilliant blue FCF aluminium lake. See section 2 NEXPOVIO contains sodium .</li></ul><p>What NEXPOVIO looks like and contents of the pack NEXPOVIO film-coated tablets are blue, round, with K20 debossed on one side.</p><p>Each outer carton contains four child-resistant inner packs. Each inner pack contains one plastic blister with 2, 3, 4, 5, or 8 tablets, providing a total of 8, 12, 16, 20, or 32 tablets.</p><p>Marketing Authorisation Holder Stemline Therapeutics B.V. Basisweg 10, 1043 AP Amsterdam Netherlands</p><p>Manufacturer(s)<br/>Stemline Therapeutics B.V. Basisweg 10, 1043 AP Amsterdam Netherlands</p><p>Berlin-Chemie AG Glienicker Weg 12489 Berlin<br/>Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien; ; esk republika; Danmark; Eesti; ; Hrvatska; Ireland; sland; ; Latvija; Lietuva; Luxembourg/Luxemburg; Magyarorsz g; Malta; Nederland; Norge; Polska; Portugal; Rom nia; Slovenija; Slovensk republika; Suomi/Finland; Sverige Stemline Therapeutics B.V. Tel: +44 (0)800 047 <a href="mailto:8EUmedinfo@menarinistemline.com">8EUmedinfo@menarinistemline.com</a></p><p>Deutschland Stemline Therapeutics B.V. Tel: +49 (0)800 <a href="mailto:0008EUmedinfo@menarinistemline.com">0008EUmedinfo@menarinistemline.com</a></p><p>Espa a Laboratorios Menarini, S.A. Tel: <a href="mailto:+34919490EUmedinfo@menarinistemline.com">+34919490EUmedinfo@menarinistemline.com</a> France Stemline Therapeutics B.V. T l: +33 (0)800 991 <a href="mailto:EUmedinfo@menarinistemline.com">EUmedinfo@menarinistemline.com</a></p><p>Italia Menarini Stemline Italia S.r.l. Tel: +39 <a href="mailto:800776EUmedinfo@menarinistemline.com">800776EUmedinfo@menarinistemline.com</a> sterreich Stemline Therapeutics B.V. Tel: +43 (0)800 297 <a href="mailto:EUmedinfo@menarinistemline.com">EUmedinfo@menarinistemline.com</a></p><p>United Kingdom (Northern Ireland) Stemline Therapeutics B.V. Tel: +44 (0)800 047 <a href="mailto:8EUmedinfo@menarinistemline.com">8EUmedinfo@menarinistemline.com</a></p><p>This leaflet was last revised in mm/yyyy.</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp7213aca022d38d404e1e1e0d23413856"/>
<resource>
<MedicinalProductDefinition>
<id value="mp7213aca022d38d404e1e1e0d23413856"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp7213aca022d38d404e1e1e0d23413856"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp7213aca022d38d404e1e1e0d23413856</b></p><a name="mp7213aca022d38d404e1e1e0d23413856"> </a><a name="hcmp7213aca022d38d404e1e1e0d23413856"> </a><a name="mp7213aca022d38d404e1e1e0d23413856-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1537/005</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: NEXPOVIO 20 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1537/005"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="NEXPOVIO 20 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
